Braden Fenske - Medipharm Labs Chief Strategy Officer
| LABS Stock | CAD 0.07 0.01 7.69% |
Insider
Braden Fenske is Chief Strategy Officer of Medipharm Labs Corp since 2019.
| Tenure | 5 years |
| Address | 151 John Street, Barrie, ON, Canada, L4N 2L1 |
| Phone | 705 719 7425 |
| Web | https://www.medipharmlabs.com |
Medipharm Labs Management Efficiency
The company has return on total asset (ROA) of (0.0717) % which means that it has lost $0.0717 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2496) %, meaning that it generated substantial loss on money invested by shareholders. Medipharm Labs' management efficiency ratios could be used to measure how well Medipharm Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.36. At this time, Medipharm Labs' Fixed Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | INSIDER Age | ||
| Amy Schwalm | OrganiGram Holdings | N/A | |
| Peter Amirault | OrganiGram Holdings | 58 | |
| CPA CPA | OrganiGram Holdings | 55 | |
| Tina Shannon | OrganiGram Holdings | N/A | |
| Perry Antelman | Charlottes Web Holdings | 60 | |
| Julie Chamberlain | OrganiGram Holdings | N/A | |
| Timothy Emberg | OrganiGram Holdings | N/A | |
| Richard Mohr | Charlottes Web Holdings | 64 | |
| Cory Pala | Charlottes Web Holdings | N/A | |
| Sherry Porter | OrganiGram Holdings | 63 | |
| Cameron Bishop | OrganiGram Holdings | N/A | |
| Matthew Rogers | OrganiGram Holdings | N/A | |
| Andres Gortari | Charlottes Web Holdings | 48 | |
| Dexter John | OrganiGram Holdings | 49 | |
| Geoff Riggs | OrganiGram Holdings | N/A | |
| Beena Goldenberg | OrganiGram Holdings | 60 | |
| Raymond Gracewood | OrganiGram Holdings | N/A | |
| Jacques Tortoroli | Charlottes Web Holdings | 65 | |
| CFA CA | OrganiGram Holdings | 51 | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0717 |
Medipharm Labs Corp Leadership Team
Elected by the shareholders, the Medipharm Labs' board of directors comprises two types of representatives: Medipharm Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medipharm. The board's role is to monitor Medipharm Labs' management team and ensure that shareholders' interests are well served. Medipharm Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medipharm Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shelley Martin, Independent Director | ||
| Saravan Subramaniam, Vice Chain | ||
| Nigel Dewsbury, Head Quality | ||
| Geoffrey Marr, Executive Counsel | ||
| Brett Moon, Vice Sales | ||
| Kirk Binns, Executive Accounts | ||
| Sybil Taylor, Chief Marketing Officer | ||
| Robert Kwon, Chief Financial Officer | ||
| Paul Tam, Director | ||
| Chris Halyk, Independent Director | ||
| Miriam McDonald, Director | ||
| David Pidduck, CEO Director | ||
| Keith Strachan, President Director | ||
| Greg Hunter, Chief Officer | ||
| Warren Everitt, Managing Director - MediPharm Labs Australia | ||
| Chris Taves, Director | ||
| Patrick McCutcheon, Chairman of the Board, Chief Executive Officer and Director | ||
| David Mayers, Chief Operating Officer | ||
| Christopher Hobbs, Director | ||
| Braden Fenske, Chief Strategy Officer | ||
| Marufur Raza, Director |
Medipharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medipharm Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0717 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 16.34 M | ||||
| Shares Outstanding | 411.12 M | ||||
| Shares Owned By Insiders | 4.45 % | ||||
| Shares Owned By Institutions | 0.71 % | ||||
| Number Of Shares Shorted | 252.82 K | ||||
| Price To Earning | 172.00 X |
Pair Trading with Medipharm Labs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.
The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medipharm Stock
Medipharm Labs financial ratios help investors to determine whether Medipharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.